Testing fostamatinib for lung transplant patients with new donor-specific antibodies
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a drug called fostamatinib to see if it is safe and tolerable for lung transplant patients who develop new antibodies against their donor lung. It aims to prevent rejection without harming the new lung.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are receiving your first lung transplant.
- You have developed new antibodies against your donor lung, first detected 21 days or more after transplant.
- You signed up for this study within 30 days of those antibodies being found.
- Your new lung is working well with no signs of rejection at the time you join.
- You have adequate liver and kidney function, and a healthy blood cell count.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune-suppressing medicine to stop a serious complication called primary graft dysfunction that can happen soon after a lung transplant. It may help people who are already on the transplant waiting list and plan to receive a standard anti-rejection drug regimen.
This trial tests whether a faster test for lung infections can help doctors choose the right antibiotics sooner after a lung transplant. It aims to reduce infections and improve recovery.
This trial tests a special form of tacrolimus (Envarsus) taken once daily to prevent organ rejection in people who recently received a first lung transplant. The study will follow patients for at least 12 months.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
This trial tests a new combination of radiation and antibody treatment for people receiving a liver transplant at Stanford. The goal is to help your new liver last longer by training your immune system to accept it while reducing the need for lifelong anti-rejection drugs.
This study tests a drug called fostamatinib to treat severe lung failure (ARDS) in people who are on a breathing machine. The goal is to see if it helps the lungs recover faster.
Hear when a new Lung Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.